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Abstract
MicroRNAs (miRNAs) are a class of small noncoding RNAs that regulate gene expression by targeting mRNAs to trigger
either translation repression or mRNA degradation. miR-125b is down-regulated in human breast cancer cells compared
with the normal ones except highly metastatic tumor cells MDA-MB-231. However, few functional studies were designed to
investigate metastatic potential of miR-125b. In this study, the effects of miR-125b on metastasis in human breast cancer
cells were studied, and the targets of miR-125b were also explored. Transwell migration assay, cell wound healing assay,
adhesion assay and nude mice model of metastasis were utilized to investigate the effects of miR-125b on metastasis
potential in vitro and in vivo. In addition, it was implied STARD13 (DLC2) was a direct target of miR-125b by Target-Scan
analysis, luciferase reporter assay and western blot. Furthermore, activation of STARD13 was identified responsible for
metastasis induced by miR-125b through a siRNA targeting STARD13. qRT-PCR, immunofluorescent assay and western blot
was used to observe the variation of Vimentin and a-SMA in breast cancer cells. In summary, our study provided new
insights into the function of miR-125b during the metastasis of breat cancer cells and also suggested the role of miR-125b in
pro-metastasis by targeting STARD13.
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Introduction
MicroRNAs (miRNAs), a series of endogenous, non-coding and
single-strand RNA approximately containing 22 nucleotides,
regulate messenger RNAs at the post-transcriptional level through
binding to complementary sequences in un-translated regions
(UTR) of target mRNAs bearing fully complementary target sites,
inducing their degradation or repressing translation. [1,2]
miRNAs target abundant genes which regulate a great variety of
biological effects, including proliferation, apoptosis, stem cell self-
renewal and differentiation. [3,4] Moreover, expression of miRNA
is significantly modulated in a tissue- and developmental stage-
specific manner. [5] Recent studies analyzed miRNA profiles and
functions in cancer provided valuable information on the
molecular pathogenesis of several tumor types, including breast,
lung, colon and prostate cancer, hepatocellular carcinoma and
glioblastoma [6,7,8]. It is widely accepted that miRNAs play an
important role in all steps of tumorigenesis.
miR-125b, a human homologue of lin-4, downregulated in
bladder, ovarian and breast tumors with functions as a tumor
suppressor. [9,10,11,12] However, miR-125b not only over-
expresses in pancreatic cancer, oligodendroglial tumors, prostate
cancer, myelodysplastic syndromes and acute myeloid leukemia,
but also promotes cell proliferation in prostate cancer cells,
enhances invasive potential in urothelial carcinomas and sup-
presses p53-dependent apoptosis in human neuroblastoma cells.
[13,14,15,16] Latest report identified miR-125b as a basal-like
microRNAs and was significantly elevated in highly tumorigenic
human breast cancer stem cells [17] and malignant myoepithe-
lioma breast cancer cells. [18] Even though great evidence
indicated the important roles of miR-125b in the biological
properties of breast cancer, few reports to date studied the
relationship between miR-125b and the metastatic potential of
breast cancer. The expression of miR-125b was low in most breast
cancer cell lines MCF-7, T47D, SK-BR3, BT-20 and MDA-MB-
175 compared to mammary epithelial cell MCF-10A, but high in
MDA-MB-231 which is a highly metastatic breast cancer cells.
[19] Based on the evidence above, it is theoretically proposed that
the expression of miR-125b is closely related to the metastatic
activity of tumor cells.
Tumor metastasis is the most prominent problem in clinical
treatment of cancer, as most cancer mortality is associated with
disseminated disease rather than the primary tumor. There are
two leading theories about the origin of metastasis, Epithelial to
mesenchymal transition (EMT) hypothesis [20,21,22] and cancer
stem cell hypothesis. [23] EMT, characterized as loss of polarity
and epithelial markers (including junctional and cell-cell adhensive
proteins), [24] plays a role in cellular differentiation and tumor
invasion. Cancer stem cell hypothesis suggests that cancer stem
cells could initiate a primary tumor, and thus be able to initiate
metastasis. It is well known that breast cancer stem cells have
mesenchymal features and correlate with metastasis and poor
prognosis. [25] Markers are used to define the mesenchymal
phenotype such as vimentin, a-SMA (smooth muscle alpha-actin),
N-cadherin and loss of E-cadherin. [21] To fully elaborate the
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cancer cells will provide important information on the mechanisms
of tumor metastasis.
Although miR-125b has been implicated with functions as
a tumor suppressor in breast tumors, its functional role in
metastasis has not been clearly described. In the present study,
we began by examining the function of miR-125b on cell
migration. Interestingly, we found that miR-125b has a role of
pro-metastasis in vitro. To further validate this pro-metastasis role,
we designed a node mice model and the same result has been
obtained. In addition, we investigated the mechanisms of pro-
metastasis for miR-125b and found that STARD13, (StAR-related
lipid transfer domain containing 13) also known as DLC2 (deleted
in liver cancer cells) with a Rho-GAPase-activating protein
(RhoGAP), [26] was a target protein of miR-125b. The activation
of STARD13 was responsible for MCF-7 metastasis induced by
miR-125b was also validated. Further examination of the
consequences of gain- and loss-of-function of miR-125b in breast
cancer cells, we investigated the influence of miR-125b on the
expression of a-SMA and vimentin, two classical mesenchymal
phenotype markers and provided new insights into the function of
miR-125b in cancer metastasis.
Materials and Methods
Reagents, Cell Culture, and Treatment
MCF-7, MDA-MB-231, MDA-MB-435, MCF-10A, MCF-7/
ADR and HEK-29 cells were obtained from the ATCC
(Manassas, Virginia, USA). MCF-7 and MCF-7/ADR were
cultured in RPMI 1640 medium (Gibco/BRL, Grand Island,
NY) containing 10% calf serum (CS); MDA-MB-231 was cultured
in L-15 medium containing 10% fetal bovine serum (FBS); MDA-
MB-435, MCF-10A and HEK-293 was cultured in complete
medium DMEM (Gibco) containing 10% fetal bovine serum (FBS)
with 1 mM L-glutamine. All medium used in the study were
supplemented with penicillin and streptomycin. miRNA over-
expression and inhibition: miR-125b-mimics, inhibitors (59-
ucacaaguuagggucucaggga-39 ) and Normal Control (NC) were
designed through the reference of miRbase Database (www.
miRbase.org and ) and synthesized in Biomics Biotechnology Inc
(Biomics, Jiang Su, China) with OMe modification, 50 nM of
which were transfected into cells using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). STARD13 antibody (sc-67843) were
purchased from Santa Cruz Biotechnology Inc (Santa Cruz,
California, USA), vimentin antibody (catalog#2707-1) and a-
SMA antibody (catalog#1184-1) form Epitomics Inc (Epitomics,
California, USA).
mRNA and miRNA Quantification
Total RNA was extracted using Trizol reagent (Invitrogen,
USA). Reverse transcription-PCR was performed with M-MLV
(Promega, USA ) following standard protocols.
For miRNA qPCR, the miR-125b primer, U6 primer and
EzOmics SYBR qPCR kit were purchased from Biomics. Ampli-
fication procedure was as follows: 94uC for 5 min, followed by 30
cyclesat94uCfor30 s,61uCfor45 s,finallyby72uCfor10 min.For
RT-PCR, The primer sequences of various genes were demen-
strated as follows: GAPDH: 59-AAGGTCGGAGTCAACG-
GATT-39, and 59-CTGGAAGATGGTGATGGGATT-39;
STARD13: 59-AGCCCCTGCCTCAAAGTATT-39, and 59-
ATGGGCGTCATCTGATTCTC-39; Vimentin: 59-
CCCTCACCTGTGAAGTGGAT-39, and 59-TCCAG-
CAGCTTCCTGTAGGT-39; a-SMA: 59-CATCATGCGTCTG-
GATCTGG-39, and 59-GGACAATCTCACGCTCAGCA-39.
Amplification procedure was 94uC for 5 min, followed by 30 cycles
at 94uC for 30 s, 57uC for 45 s, 72uC for 45 s, finally by 72uC for
10 min.
Adhesion Assay
Cell adhesion assay was assayed as described previously with
sight modifications. [27] Microtiter wells were coated with
fibronectin (Sigma, St. Louis, Missuouri) overnight. The wells
were blocked for 30 min with 0.5% BSA in PBS. Cells were
trypsinized and suspended at a final concentration of 5610
5 cells/
ml in serum-free medium. miR-125b-mimics, miR-125b-inhibitor
and NC were transfected into the cells for 24 h prior to seeding.
The colorimetric MTT-assay was used to determine the number
of remaining cells (adherent cells).
Wound Healing Assay
MCF-7 cells were seeded into a 6-well plate and allowed to grow
to 70% confluency in complete medium. Cell monolayers were
wounded by a plastic tip (1 mm) that touched the plate as
described previously. [28] Wounded monolayers were then
washed for several times with PBS to remove cell debris and
transfected with miR-125b-mimics and miR-125b-inhibitor and
incubated for 24 h. Cells migrated into wound surface and the
average distance of migrating cells was determined under an
inverted microscopy at designated time points.
Transwell Migration Assay
Transwell migration assays were carried out using 24-well
MILLIcell Hanging Cell Culture inserts 8 mm PET(MILLIPORE)
as described previously. [29] Briefly, Cells harvested 48 h after
transfection using 5 mM EDTA in PBS, were added (1.25610
5
cells/well) in serum-free medium to triplicate wells of BD
BioCoatTM MatrigelTM Invasion Chambers (BD Bioscience)
and complete medium containing 10% FBS or CS was added to
the lower chamber. The invasion chambers were processed for
24 h followed the manufacturer’s protocols, and migrated cells
were stained using methanol and viola crystalline solution. Five
random fields from each of the triplicate invasion assays were
counted using phase contrast microscopy.
Plasmid Construction and Establishment of Stable miR-
125b Over-expressing Cells
The procedure of pre-microRNA plasmid construction was
referred to the method described by Galardi et al. [30] In brief, the
pre-miR-125b sequences were amplified by PCR from human
genomic DNA using the following primers: forward/HindIII, 59-
GGC AAG CTT AAC ATT GTT G CGC TCC TCT CA-39;
reverse/BamHI, 59-TAT GGA TCC TTC CAG GATGCA AAA
GCA CGA-39. After being digested with HindIII and BamHI, the
PCR product was cloned into pSilencer 4.1 vector (Ambion,
Austin, USA) and the constructs were verified by DNA
sequencing. Expression of miR-125b was detected by qRT-PCR
analysis after 48 h from transfection pSilencer-125b and pSilen-
cer-control plasmid into human breast cancer cells MCF-7 for
48 h. Positive cells were selected with 2 ug/ml G418 was
confirmed by qRT-PCR.
Animal Models
Five- to six-week-old female athymic BALB/c nude mice were
purchased from Hospital of Nanjing Military Region (Jiang Su,
China). All experimental protocols were approved by Ethics
Committee for Animal Experimentation of China Pharmaceuti-
cal University. Experimental metastasis assays: 1610
6 cells (for
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medium were injected into the lateral vein of six-week-old female
athymic BALB/c nude mice. The NIR-imaging model was
referred to the method described by Liu F and et al. [31] For
NIR near infrared imaging, 3 weeks after the injection cells, each
mouse was injected via tail vein with 200 ml folate-polyethylene
glycol. The subjected mouse was firstly anesthetized and imaged
in NIR-imaging system at predetermined intervals of 0 h and
4 h. To further confirm the pathological changes in NIR
metastasis model, the mice were euthanized after injection for
24 h. The lungs, liver and kidney were dissected out, photo-
graphed, fixed in 4% PFA overnight, cry-protected in 30%
sucrose in PBS and frozen in OTC embedding media (Tissue
Tek) and stained with H&E.
Luciferase miRNA Target Reporter Assay
pMiR-Report Fluc vectors (Ambion) was used to introduce the
portion of the 3’ UTR of STARD13 mRNA containing the
putative binding site for miR-125b. Both sense and antisense
oligonucleotide templates were synthesized as 59-mer and
annealed as described. The annealed oligonucleotides were
digested and ligated at HindIII and SpeI sites into pMiR-Report.
The sequences used in these studies were:
STARD13-wt:
59-CTAGTTTTTGCCCAGTGTGACATCAAACTCAGG-
GAAGAGGAAGCTAAAGTGACGAGTGA-39 59AGCTT-
CACTCGTCACTTTAGCTTCCTCTTCCCTGAGTTT-
GATGTCACACTGGGCAAAAA-39
STARD13-mut:
59-CTAGTTTTTGCCCAGTGTGACATCAAAACCGTAG-
GAGAGGAAGCTAAAGTGACGAGTGA -3 59-AGCTT-
CACTCGTCACTTTAGCTTCCTCTCCTACGGTTTT-
GATGTCACACTGGGCAAAAA-39
HEK 293T cells were co-transfected with the pMiR-Report
vectors containing the STARD13 3’UTR with wild-type (wt) or
mutant (mut) sequences and mimics-miR-125b, inhibitor or NC.
The cells were lysed and luciferase activity was measured using
a luminometer 48 h later. An expression cassette for Rluc was co-
transfected and used to normalize the Fluc values expressed from
the pMiR-Report constructs.
Western Blotting
After various treatments for indicated intervals, cells were lysed
in lysis buffer. The cells used for phospho-lysates were lysed with
lysis buffer enriched with protease inhibitors cocktail, 1 mM
sodium fluoride, and 1 mM sodium orthovanadate. Protein
(40 mg) were separated on a 12% SDS-polyacrylamide gel and
transferred electrophoretically onto polyvinylidene difluoride
membranes (Millipore, USA). The membranes were blocked with
10% milk in Tris-buffered saline/0.1% Tween 20 for 2 h,
subsequently blotted with primary antibodies then blotted with
horseradish peroxidase-conjugated secondary antibody for 1 h.
The protein bands were visualized with enhanced chemilumines-
cence detection system (Amersham, UK). Protein levels were
quantified by density analysis using Quantity One software
(BioRad).
Trnasfection of siRNA
Short interfering RNA against the human STARD13(DLC2)
sense: 59-CCCUGCCUCAAAGUAUUCAdTdT-39; anti-sense:
59-UGAAUACUUUGAGGCAGGGdTdT, and the universal
negative control siRNA were used. The siRNAs were transfected
into MCF-7 by using Lipofectamine2000 (Invitrogen, Carlsbad,
CA) per the manufacturer’s protocol.
Immunofluorescent Assay
Cells were seeded into a 6-well plate, after various treatments,
the cells at indicated intervals were fixed in 4% paraformaldehyde
for 20 min and blocked with 3%BSA in PBS for 1 h at room
temperature. Subsequently blotted with primary antibodies
(Vimentin antibody Epitomics catalog#2707-1) and then blotted
with FITC- conjugated secondary antibody for 1 h then blotted
with DAPI fluorescence for 1 h and observed with the confocal
laser scanning.
Statistical Analysis
The experimental results were shown as the mean 6 SEM for
each group. Data were assessed by analysis of variance (ANOVA).
If this analysis indicated significant differences between the group
means, then each group was compared with normal control group
(NC) by using the Dunnett t (2-sided) analysis. P,0.05 was
considered to be statistically significant.
Results
miR-125b Promoted Metastasis of MCF-7 and MDA-MB-
231 Cells
q-RT-PCR was used to test the expression of miR-125b in
different metastatic potential breast cancer cell lines of MCF-7,
MDA-MB-231, MCF-7/ADR MDA-MB-435, and MCF-10A.
Results in Fig.1A showed that the expression of miR-125b in
MDA-MB-231, highly metastatic tumor cells, was 5.35 folds more
than MCF-10A and 22.6 folds than MCF-7 (Figure 1A).
Cell motility was a measure of metastatic potential of cancer
cells. The motility of human breast cancer cells lines MCF-7 and
MDA-MB-231 were examined by wound healing assay when
treated with mimics, inhibitor and NC. Confluent monolayers of
cells were scratched to be wounded and cultured for 24 h or 36 h.
(Figure 1B) The treatment with miR-125b mimics led to
significantly increase of wound healing cell migration compared
to the treatment of NC and inhibitor of miR-125b in MCF-7 cells.
For miR-125b high-expression cell lines MDA-MB-231, cell
migration was inhibited when treated with miR-125b-inhibitor.
Adhension of tumor cells to extra-cellular matrix and basement
membranes were considered to be the initial step in the invasive
process for metastatic tumor cells. We examined the influence of
miR-125b on the adhension activities of breast cancer MCF-7 and
MDA-MB-231 cells to the substrates precoated with fibronectin,
which is a basement member component. After transfected with
mimics-miR-125b, the adhesion activity was increased about 1.42
fold in MCF-7; when treated with miR-125b inhibitors, the
adhesion activity was decreased compared with NC group and the
inhibition rate was about 45.8% (Figure.1C).
To investigate whether the differential expression of miR-125b
was correlated with tumor invasion, MCF-7 and MDA-MB-231
cells were transfected with mimics-miR-125b, inhibitor-miR-125b
and nonspecific control miRNA (NC) into MCF-7 and MDA-MB-
231 cells, transwell migration assay was used to investigate
metastasis activity. As shown from the images in Fig.2A, when
the expression of miR-125b was upregulated by mimics-miR-125b
in MCF-7 cell lines, the cells demonstrated high-migration
potentiality compared to cells treated with inhibitor-miR-125b
or NC. While the expression of miR-125b was down-regulated by
adding inhibitor-miR-125b in MDA-MB-231 cell line, the cells
migration ability was decreased significantly (P,0.001). Interest-
ingly, miR-125b showed a pro-metastasis function in human
breast cancer cell lines MCF-7 and MDA-MB-231. qRT-PCR was
used to analyzed the expression of miR-125b when treated with
mimics, inhibitor and NC and the result showed that the
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migration ability of breast cancer cell lines MCF-7 and MDA-
MB-231 (Fig.2C).
To test whether miR-125b was pro-metastasis in vivo,
a metastasis animal model was designed. MCF-7-125b cells,
MCF-7-pSilencer-control and physiological saline were injected to
BALB/c nude mice and after 3 weeks injected folate-polyethylene
glycol to diagnose metastatic focus. As shown in Figure 3A, in the
group of up-regulated miR-125b expression, it was found that 4
cases had kidney metastasis, 1 case had lung metastasis and one
had eye metastasis. To further confirm the pathological changes of
NIR metastasis model, the mice were euthanized 24 h post-
injection by pathologic examination. As shown in Figure 3B, we
found that all of metastasis focuses developed nucleus disorder
which were diagnosed by NIR metastasis model. We dissected the
mouse and found one case had liver metastasis (Figure 3C) and
further pathologic examination confirmed this liver metastasis
arising from the metabolism of NIR probe Folate-Polyethylene
Glycol was through hepato-enteric circulation.
miR-125b Directly Targeted the Tumor Suppressor gene
STARD13
It is generally accepted that miRNAs exert their function
through regulating the expression of their downstream target
gene(s). To investigate the target of miR-125b in breast cancer,
systemic bioinformatic publicly available algorithms were used to
analyze and identify potential targets. We found that human
STARD13 39-UTR contained putative miR-125b complementary
sites. A complementary site for the seed region of miR-125b was
contained by STARD13 39-UTR (Figure 4A).
To validate whether STARD13 is a bona fide target of miR-
125b, a human STARD13 3’UTR fragment containing wild-type
or mutant miR-125b-biding sequences was sub-cloned to the
downstream of the Renilla luciferase reporter gene. When miR-
125b-mimics or miR-125b-inhibitor were cotransfected with the
reporter plasmid, the relative luciferase activity of the reporter
containing wild-type STARD13 3’-UTR was obviously suppressed
while the luciferase activity of the reporter containing mutant
STARD13 3’-UTR was unaltered. It indicated that miR-125b
may downregulate expression of STARD13 gene expression
through miR-125b-biding sequences at the 3’UTR of STARD13
gene (Figure 4B).
To further study the relationship between miR-125b and the
expression of STARD13, qRT-PCR and western bolt were
performed to examine the effect of over-expression or down-
regulated of miR-125b on the mRNA and protein levels of
STARD13 in cancer cells. It showed that there were significant
inverse correlations between the expression of miR-125b and
STARD13 protein (Figure 4D and E,) for breast cancer cells.
However, there was no correlation between miR-125b and the
STARD13 expression in mRNA level (Figure 4C).
miR-125b Promoted Metastasis by Targeting STARD13 in
MCF-7
We validated that miR-125b promoted breast cancer metastasis
in vivo and in vitro and that STARD13 was one of miR-125b
targets was also validated in previous results. To further explore
whether miR-125b promoted metastasis by targeting STARD13,
a siRNA targeting STARD13 was designed. It was shown in
Figure 5A, we got an expected inhibition effect after transfected
with siRNA-STARD13 for 72 h. In addition, the motility of
Figure 1. Effects of miR-125b on cell migration in MCF-7 and MDA-MB-231 in vitro. (A) Expression of miR-125b in MCF-7, MDA-MB-435,
MCF-7/ADR, MDA-MB-231and MCF-10A cells measured by real-time RT-PCR. The normalized miR-125b expression for MCF-10A was set 1. Data were
present as mean 6 SEM, n=3, *p,0.05, **p,0.01 vs. MCF-10A. (B) Effects of miR-125b on MCF-7 cell migration in vitro. Movement of MCF-7 and
MDA-MB-231 cells into the wound was shown for mimics,inhibitor tranfected and untranfected cells and quantification of the wound healing assay.
Data are presented as mean6SEM of three separate experiments, n=3**p,0.01 vs. control group. (C) Effects of miR-125b on adhesion to fibronectin
of MCF-7 and MDA-MB-231 cells. Data were present as mean 6 SEM, n=3, *p,0.05 vs. NC group in MCF-7 and #p,0.05 vs. NC group in MDA-MB-
231 cell lines.
doi:10.1371/journal.pone.0035435.g001
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healing assay (Figure 5B). Confluent monolayers of cells were
scratched to be wounded and cultured for 36 h. The treatment
with siRNA-STARD13 led to significantly increased wound
healing cell migration compared to the treatment of NC or
Normal group in MCF-7 cells.
Further we investigated the relationship between STARD13
and invasion potential in breast cancer cells by transwell migration
assay with co-transfection of siRNA-STARD13, miR-125b mimics
and siRNA-STARD13, miR-125b inhibitor and siRNA-
STARD13 and NC group. It was shown in Figure 5C, cells
showed high-migration potentiality compared to cells of NC or
Normal group when down-regulated STARD13 by siRNA-
STARD13 (Figure 5D); the group which cotransfected with
siRNA-STARD13 and miR-125b mimics displayed significantly
difference compared with siRNA-STARD13 group, while the
siRNA+miR-125b- group had no significant difference compared
to siRNA-STARD13 group. Interestingly, these results suggested
that miR-125b regulated metastasis not only by targeting
STARD13 but also by some other unknown mechanisms.
Earlier Scott et al. restored that miR-125b expression in
SKBR3 cells which over-express ERBB2 [32]and reported
a decreased cell migration due to targeting of ERBB2 by miR-
125b. We investigated the influence of miR-125b on HER2
signaling pathway in ERBB2-negative breast cancer cell lines
MCF-7. [33] Western blotting for phosphorylated ERK1/2 and
AKT, downstream targets of ERBB2, demonstrated that there was
no significant decrease in MCF-7(Figure 5E). These results
indicated that HER2 signaling pathway did not play an important
role in miR-125b regulated ERBB2-negative breast cancer
metastasis.
Vimentin and a-SMA were Involved in miR-125b
Regulated Metastasis
Epithelial to mesenchymal transition (EMT), characterized as
loss of polarity and epithelial markers (including junctional and
cell-cell adhesion proteins), has long been known to play a role in
cellular metastasis and tumor invasion. Markers used to define the
mesenchymal phenotype include the upregulation of vimentin, a-
SMA and N-cadherin, and loss of E-cadherin. To further examine
whether miR-125b would induce EMT, breast cancer cell lines
MDA-MB-231 and MCF-7/ADR were used to observe the
variation of vimentin and a-SMA because MCF-7 is vimentin-
negative cell line. Consistent with metastasis ability, after transient
transfection with miR-125b-mimics in MCF-7/ADR, both
vimentin and a-SMA mRNA levels were increased by 5.2 and
6.34 fold compared to NC group (Figure 6A). Protein levels of
vimentin and a-SMA were also increased (Figure 6B) by 2.70 and
1.92 fold (Figure 6C). In contrast, mRNA and protein levels of
Figure 2. Effects of miR-125b on cell invasion in MCF-7 and MDA-MB-231 in vitro. (A) Photographs of the cell invasion through the
polycarbonate membrane stain by crystal violet. The migratory cell numbers of both cell lines transfected with miR-125b mimics were significantly
more than that of cells transfected with inhibitor respectively. (B) OD570 of stain crystal violet. Data were present as mean 6 SEM, n=3, *p,0.05,
**p,0.01 vs. NC group. (C) Real-time PCR analysis of the expression of miR-125b with transfected miR-125b-mimics, miR-125b inhibitors, NC and
untranfected one in MCF-7 and MDA-MB-231 cells. 2DDCt=2 (Ctx-CtU6x)-(CtNCx-CtU6NC). Data were present as mean 6 SEM, n=3, **P,0.01 vs.
NC group in MCF-7,
##P,0.01 vs. NC group in MDA-MB-231.
doi:10.1371/journal.pone.0035435.g002
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34.66% in MDA-MB-231 with miR-125b-inhibitor transient
transfection.In sum, the results indicated that mRNA and protein
levels of vimentin and a-SMA were positively correlated with the
expression of miR-125b. It suggested that miR-125b was
important in regulating reorganization of actin cytoskeleton and
the maintenance of cell morphology.
Immunofluorescent assay was used to investigate the effect of
miR-125b on expression and distribution of vimentin in breast
cancer cell lines MDA-MB-231 and MCF-7/ADR. The expres-
Figure 3. Effects of miR-125b on breast tumor metastasis in vivo. (A) Photographs of diagnosed tumor metastasis by NIR-imaging system, 3
weeks after injection breast cancer cells MCF-7 and MCF-7-125b NIR probe Folate-Polyethylene Glycol was injected to BALB/c nude mice and
formation of imaged at 0 h and 4 h after injection of NIR-probe. (B) Images of metastatic focuses in patho-histological examination stained with H&E.
(C) Images of representative liver dissected from mouse and patho-histological examination stained with H&E.
doi:10.1371/journal.pone.0035435.g003
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predicted using Targetscan 5.1. (A) pMiR-Report vectors containing the wt or mut miR-125b binding site from the 39UTR of STARD13 mRNA, and miR-
125b-mimics or NC, as well as an expression cassette for Rluc were co-transfected into HEK-293T cells. Two days later Fluc activity in cells was
measured and normalized to Rluc activities two days after. Data were present as the mean 6 SEM, n=3, *p,0.05 vs. NC group. (C) Breast cancer cell
lines of MCF-7 and MDA-MB-231 cells were transfected with miR-mimics, miR-125b-inhibitors and control miRNA, the gene expression of STARD13
was detected by real-time RT-PCR after 48 h. Data were present as the mean 6 SEM, n=3
DDp,0.001 NC group in MDA-MB-231 vs. NC group in MCF-
7; (D) Breast cancer cell lines of MCF-7 and MDA-MB-231 cells were transfected with miR-mimics, miR-125b-inhibitors and control miRNA, STARD13
protein and b-actin after 72 h were detected by western blot. (E) Quantitative data of densitometric analyses. The ratio of STARD13 protein and
mRNA levels to b-actin and GAPDH were displayed as mean 6 SEM, n=3, *p,0.05, **p,0.01 vs. NC group;
DDp,0.001 NC group in MDA-MB-231 vs.
NC group in MCF-7.
doi:10.1371/journal.pone.0035435.g004
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treated with miR-125b-mimics; (Figure 7A) while the expression
was down-regulated compared with NC or normal control group
in MDA-MB-231 cells (Figure 7B). Meanwhile, the morphology of
cells treated with miR-125b-inhibitor changed from long shuttle-
shape to spherical.
Figure 5. miR-125b regulated breast cancer metastasis by targeting STARD13. (A) Expression of STARD13 and b-actin were detected by
western blot treated with siRNA-STARD13 and NC. (B) Effects of STARD13 on MCF-7 cell migration in vitro. Wound healing assay for MCF-7 cells was
carried out by adding siRNA-STARD13 and NC and photographed at 0 h and 36 h. (C) Effects of miR-125b and STARD13 on cell invasion in MCF-7 cells
in vitro. Photographs of the cell invasion through the polycarbonate membrane stained with crystal violet and DAPI. (D) OD570 of stain crystal violet.
Data were present as mean 6 SEM, n=3, *p,0.05, **p,0.01 vs NC group;
Dp,0.05, group of cotransfected with siRNA-STARD13 and miR-125b
mimics vs group of treatment with siRNA-STARD13. (E) Effects of miR-125b on ERK1/2 and AKT phosphorylation. MCF-7 cells were transfected with
miR-125b- mimics, miR-125b-inhibitors and control RNA. After 48 h, the phosphorylation of ERK1/2 and AKT was detected by western blot.
doi:10.1371/journal.pone.0035435.g005
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Signaling Pathway
STARD13 (DLC2), a tumor suppressor protein, has growth-
suppressive and anti-metastatic effects on breast cancer cell lines
MCF-7/ADR and can inhibit the activity of RhoA. [34] We
found that miR-125b targeted STARD13 and miR-125b might
play a role in regulating vimentin and a-SMA expression.
Therefore, we speculated that inhibition of RhoA-ROCK in
MCF-7/ADR might affect the regulation function of miR-125b
on vimentin and a-SMA expression. To confirm these ideas we
used an inhibitor of ROCK to study the expression of vimentin
and a-SMA. When MCF-7/ADR and MDA-MB-231 cells were
treated with Y-27632 (inhibitor of ROCK) after transient
transfection with miR-125b-mimics, it completely blocked the
upregulation of a-SMA induced by miR-125b rather than the
regulation of vimentin (Figure 8). It suggested that miR-125b
regulated a-SMA in MCF-7 cells through STARD13-RhoA-
ROCK signaling pathway.
Figure 6. miR-125b affected vimentin and a-SMA at gene level and protein level. (A) MCF-7/ADR and MDA-MB-231 cells were transfected
with miR-125b-mimics, miR-125b-inhibitors and control RNA. After 48 h, the expression of vimentin anda-SMA was detected by real-time RT-PCR.
Data were present as mean 6 SEM, n=3, *P,0.05,**P,0.01 vs. NC group in MCF-7/ADR;
#P,0.05,
##P,0.01 vs. NC group in MDA-MB-231;
DDP,0.01
NC group in MDA-MB-231 vs. NC group in MCF-7/ADR. (B) Expression of vimentin and a-SMA by western blot with got or lost functions of miR-125b.
(C) Representative quantitative data of densitometric analyses. The ratios of vimentin and a-SMA to b-actin were present as mean 6 SEM, n=3,
*p,0.05, **p,0.01 vs. NC group.
doi:10.1371/journal.pone.0035435.g006
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MCF-7/ADR, respectively. Green, vimentin was immunostained with anti-vimentin; blue, nuclei were stained with DAPI.
doi:10.1371/journal.pone.0035435.g007
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MicroRNAs are known to regulate the expression of genes
involved in the control of tumor development, proliferation,
apoptosis and stress response. [35,36,37,38] It has been demon-
strated that miRNAs aberrantly expressed in many human
cancers, including breast cancers, but their functions and
mechanisms in tumorigenesis isn’t explicit. Our results obtained
from gain-of-function and loss-of-function approaches indicated
that miR-125b was positively correlated with the invasive and
migratory abilities of breast cancer cells in vitro. For human breast
cancer cell lines MCF-7 with low metastatic ability and low
expression of miR-125b, up-regulation of the expression of miR-
125b permitted MCF-7 cell lines to gain a high metastasis
potentiality (Figure1B 2A and Figure 3). In MDA-MB-231 cell
lines with high expression of miR-125b, the cells migration ability
was decreased significantly with down-regulation of the expression
of miR-125b by the miR-125b inhibitor (Figure2A). In the study of
nude mice model, we validated that miR-125b had a role of pro-
metastasis in vivo by a probe for NIR-imaging. (Figure 3) Using
tumor targeting probe could to determine metastasis focuses
widely, conveniently, accurately compared to traditional metasta-
sis experiment.
miRNAs regulate functions of their target genes by binding to
the complementary regions of messenger transcripts to repress
their translation or to regulate their degradation. STARD13
encodes a protein that contains a sterile alpha motif domain in the
N-terminus, an ATP/GTP-binding motif, a GTPase-activating
protein domain, and a STAR-related lipid transfer domain in the
C-terminus [26,39] STARD13, a putative tumor suppressor gene
located at chromosome 13q12.3 that has loss of heterozygosity in
hepatic cancer. Recombinant DLC2 showed GAP activity which
is specific for small GTPases RhoA and CDC42 (cell division cycle
42). STARD13 is lower expressed in breast cancer cell lines
compared with normal cells. It suppresses cell growth and
migration via the regulation of Raf-1-ERK1/2-p70S6K signaling
pathway in Hepatocellular carcinoma cells [34,40]. For the first
time, we identified STARD13 as a target of miR-125b (Figure 4)
and miR-125b would promote breast cancer cells migration via
regulating STARD13 expression (Figure 5B and 5C) by a siRNA
targeting STARD13. Interestingly, our results(Figure 5C and
8)showed that MCF-7 cells got a higher metastasis potentiality
compared to siRNA group when co-transfected with miR-125b-
mimics and siRNA-STARD13. It may suggest that miR-125b
regulate metastasis not only through targeting STARD13 but
through also by some other unknown mechanisms.
The question of whether miR-125b is a proto-oncogene or anti-
oncogene in breast cancers is controversial. Scott et al. reported
that oncogene ERBB2 was a target of miR-125b [32] but in
another report, Zhou et al. found that miR-125b down-regulated
the expression of pro-apoptotic BCL-2 antagonist killer1 (Bak1)
and miR-125b have no influence on expression of ERBB2 in
Figure 8. Effects of miR-125b on vimentin and a-SMA expression in MCF-7/ADR and MDA-MB-231 with ROCK inhibitor in vitro. (A B)
Effects of miR-125b and Y-27632 on a-SMA and Vimentin expression. MCF-7/ADR and MDA-MB-231 cells were transfected with miR-125bmimics or
control RNA respectively. After 24 h, cells were incubated with or without Y-27632; after 72 h, a-SMA protein, vimentin and b-actin were detected by
western blot. (C D) Quantitative data of densitometric analyses. The ratio of a-SMA protein to b-actin were present as mean 6 SEM, n=3, *p,0.05, vs.
NC group of a-SMA expression
#p,0.05, vs. group of cotransfected with miR-125b and Y-27632 of a-SMA expression.
doi:10.1371/journal.pone.0035435.g008
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time, miR-125b was considered as an anti-oncogene because of
miR-125b was down-regulated in breast cancer. But lasted
research shown that miR-125b was a basal-like microRNAs [18]
and was significantly elevated in highly tumorigenic human breast
cancer stem cells. [17] Patients with triple-negative tumors have
a relatively poor outcome and cannot be treated with endocrine
therapy or therapies targeted to human epidermal growth factor
receptor type 2 (HER2). [42] Most basal-like breast cancers was
characterized by an absence or low levels of expression of ER, an
absence of HER2 and often display gene-expression patterns that
are consistent with those of cells undergoing EMT. In this study,
a luminal subtype HER2-negative breast cancer cell lines MCF-7
[33]was used to investigate the influence of miR-125b on HER2
signal pathway. Our results shown that miR-125b has no
significant to decrease phosphorylation of ERK1/2 and AKT
which downstream targets of ERBB2 in HER2-negative breast
cancer cell lines MCF-7 (Fig.5E).
Cell migration occurs in the course of development of different
tissues and in several diseases including cancer and fibrosis by
inducing the expression of a-SMA and vimentin. Our results
demonstrated that miR-125b was a novel regulator for a-SMA
and vimentin in breast cancer cells (Fig.6). We found that miR-
125b significantly upregulated vimentin and a-SMA expression
while another EMT marker E-Cadherin had no significantly
changed (data not shown). Elevating vimentin and a-SMA
expression lead to a high metastasis potentiality and some
mesenchymal cell characteristics in breast cancer cells (Fig.6).
TGF-b1-induced EMT and apoptosis are closely related to the cell
cycle stage: apoptosis is induced mostly in cells at G2/M phase,
whereas EMT is only induced in cells at G1/S phase. [43] miR-
125b regulated G1/S transition through E2F3-Cyclin A2 signaling
pathway and kept cells at G1/S phase [10] may indicate an
important role of miR-125b in TGFb1-indunced EMT. Further-
more, by knockdown of miR-125b in MDA-MB-231, expression
of vimentin and a-SMA was downregulated by knockdown of
miR-125b in MDA-MB-231 (Figure.6 and 7), the cell morphology
was changed from long shuttle-shape to spherical and the cell
migration was significantly inhibited (Figure 7B and 2A). It
indicated that miR-125b was a key molecule in adjusting
reorganization of actin cytoskeleton. Elevated expression of miR-
125b induces luminal-like breast cancer cells to obtain post-EMT
or basal-like properties, which has an aggressive phenotype
characterized by high cell migration and poor clinical outcome.
[44] Semblable results were reported in latest research that the
content of miR-125b was significantly increased in basal-like
breast cells compared to luminal cells. [18] Taken together, miR-
125b plays an important role in keeping basal-like and post-EMT
properties.
Expression of the STARD13 GAP domain inhibited Rho-
mediated formation of actin stress fibers and suppressed Ras
signaling and Ras-induced cellular transformation in a GAP-
dependent manner. [45] Introduction of human STARD13 into
mouse fibroblasts showed the establishment of cell–cell contacts
and of cell–matrix interactions was crucial to obtain a fully
polarized epithelial state. [46] Rho GTPase is required for both
the establishment of a fully polarized state and a motile phenotype
upon EMT. [47,48] it can produce several factors which may
stimulate proliferation of cancer cells and facilitate their in-
filtration. The role of miR-125b in adjusting the ultrastructure and
cytoskeleton protein expression of breast cancer cell lines MDA-
MB-231 is possibly through attenuating the phosphorylation of
Rho-GTPases by silencing STARD13, as our results showed that
miR-125b promoted metastasis by downstream signaling trans-
duction pathways of STARD13. Rho family GTPases are greatly
over-expressed in breast tumors and RhoA is necessary for Ras-
mediated transformation and metastatic spread. [49,50] To
further demonstrate the mechanisms that miR-125b regulated
vimentin and a-SMA, we used an inhibitor of ROCK to
investigate RhoA-ROCK signal pathway. We identified that
miR-125b regulated a-SMA expression through STARD13-
RhoA-ROCK signaling pathway (Fig.8). miR-125b may induce
the phosphorylation of Rho-GTPases ROCK by silencing
STARD13, while the mechanisms of miR-125b regulating
vimentin expression need to be further studied.
Conclusions
In this study, we found that miR-125b played a critical role in
breast cancer metastasis. The expression of miR-125b affected the
metastatic activities of breast cancer cells in vivo and in vitro. In
addition, we found that tumor suppressor gene STARD13 was
a target protein of miR-125b. Over-expression of miR-125b
induced breast cancer cells to obtain epithelial and mesenchymal
characteristics while regulating the reorganization of actin
cytoskeleton. miR-125b up-regulated the expression of vimentin
and a-SMA both at mRNA and protein levels. The regulation of
a-SMA by miR-125b was dependent on STARD13-RhoA-
ROCK signaling pathway. Therefore, our results supported the
hypothesis that miR-125b is critical in breast cancer cells
metastasis.
Acknowledgments
We thank Prof. Qinglong Guo for providing the cell lines used in this study,
Prof. Yueqing GU for providing Folate-Polyethylene Glycol, Dr Jing Xiong
for helpful comments on the manuscript and the members of the Tao Xi
lab for helpful discussion.
Author Contributions
Conceived and designed the experiments: FT TX. Performed the
experiments: FT RZ YH. Analyzed the data: FT LG. Contributed
reagents/materials/analysis tools: TX FT. Wrote the paper: FT TX MZ.
Revised the manuscript: FT.
References
1. Carthew RW, Sontheimer EJ (2009) Origins and Mechanisms of miRNAs and
siRNAs. Cell 136: 642–655.
2. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350–355.
3. Kim VN, Nam JW (2006) Genomics of microRNA. Trends Genet 22: 165–173.
4. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 116: 281–297.
5. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA
gene expression deregulation in human breast cancer. Cancer Res 65:
7065–7070.
6. Lee YS, Dutta A (2009) MicroRNAs in cancer. Annu Rev Pathol 4: 199–227.
7. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way.
Cell 136: 586–591.
8. Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, et al. (2011) Knockdown of miR-
21 in human breast cancer cell lines inhibits proliferation, in vitro migration and
in vivo tumor growth. Breast Cancer Res 13: R2.
9. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, et al. (2004)
Expression profiling of mammalian microRNAs uncovers a subset of brain-
expressed microRNAs with possible roles in murine and human neuronal
differentiation. Genome Biol 5: R13.
10. Huang L, Luo J, Cai Q, Pan Q, Zeng H, et al. (2011) MicroRNA-125b
suppresses the development of bladder cancer by targeting E2F3. Int J Cancer
128: 1758–1769.
11. Guan Y, Yao H, Zheng Z, Qiu G, Sun K (2010) MiR-125b targets BCL3 and
suppresses ovarian cancer proliferation. Int J Cancer.
miR-125b Induces Metastasis by Targeting STARD13
PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e3543512. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, et al. (2011) miR-125b Is
Methylated and Functions as a Tumor Suppressor by Regulating the ETS1
Proto-oncogene in Human Invasive Breast Cancer. Cancer Res 71: 3552–3562.
13. Xia HF, He TZ, Liu CM, Cui Y, Song PP, et al. (2009) MiR-125b expression
affects the proliferation and apoptosis of human glioma cells by targeting Bmf.
Cell Physiol Biochem 23: 347–358.
14. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, et al. (2008)
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome
and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med
205: 2499–2506.
15. Shi XB, Xue L, Yang J, Ma AH, Zhao J, et al. (2007) An androgen-regulated
miRNA suppresses Bak1 expression and induces androgen-independent growth
of prostate cancer cells. Proc Natl Acad Sci U S A 104: 19983–19988.
16. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, et al. (2007)
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from
normal pancreas and chronic pancreatitis. JAMA 297: 1901–1908.
17. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, et al. (2009)
Downregulation of miRNA-200c links breast cancer stem cells with normal
stem cells. Cell 138: 592–603.
18. Bockmeyer CL, Christgen M, Muller M, Fischer S, Ahrens P, et al. (2011)
MicroRNA profiles of healthy basal and luminal mammary epithelial cells are
distinct and reflected in different breast cancer subtypes. Breast Cancer Res
Treat.
19. Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, et al. (2010) MUCIN 1
ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b
ONCOMIR. Genes Cancer 1: 62–68.
20. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal
transitions in development and disease. Cell 139: 871–890.
21. Tomaskovic-Crook E, Thompson EW, Thiery JP (2009) Epithelial to
mesenchymal transition and breast cancer. Breast Cancer Res 11: 213.
22. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, et al. (2009) miR-200 enhances
mouse breast cancer cell colonization to form distant metastases. PLoS One 4:
e7181.
23. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, et al. (2011) Epithelial-
mesenchymal transition and cancer stem cells: a dangerously dynamic duo in
breast cancer progression. Breast Cancer Res 13: 202.
24. Togawa H, Nakanishi K, Mukaiyama H, Hama T, Shima Y, et al. (2011)
Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an
orthologous PCK rat model of autosomal-recessive polycystic kidney disease.
Am J Physiol Renal Physiol 300: F511–520.
25. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007)
Mesenchymal stem cells within tumour stroma promote breast cancer
metastasis. Nature 449: 557–563.
26. Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, et al. (2005) Deleted in
liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of
RhoA activity. Proc Natl Acad Sci U S A 102: 15207–15212.
27. Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT (2002) Alendronate
inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate
pathway. Cancer Res 62: 2708–2714.
28. Xu L, Deng X (2006) Protein kinase Ciota promotes nicotine-induced migration
and invasion of cancer cells via phosphorylation of micro- and m-calpains. J Biol
Chem 281: 4457–4466.
29. Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF, et al. (2006) Silibinin
inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent
Res 85: 220–225.
30. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, et al. (2007) miR-
221 and miR-222 expression affects the proliferation potential of human
prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282:
23716–23724.
31. Liu F, Deng D, Chen X, Qian Z, Achilefu S, et al. (2010) Folate-polyethylene
glycol conjugated near-infrared fluorescence probe with high targeting affinity
and sensitivity for in vivo early tumor diagnosis. Mol Imaging Biol 12: 595–607.
32. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, et al. (2007)
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-
RNA miR-125a or miR-125b. J Biol Chem 282: 1479–1486.
33. Yamaguchi N, Oyama T, Ito E, Satoh H, Azuma S, et al. (2008) NOTCH3
signaling pathway plays crucial roles in the proliferation of ErbB2-negative
human breast cancer cells. Cancer Res 68: 1881–1888.
34. Nagaraja GM, Kandpal RP (2004) Chromosome 13q12 encoded Rho GTPase
activating protein suppresses growth of breast carcinoma cells, and yeast two-
hybrid screen shows its interaction with several proteins. Biochem Biophys Res
Commun 313: 654–665.
35. Wilbert ML, Yeo GW (2010) Genome-wide approaches in the study of
microRNA biology. Wiley Interdiscip Rev Syst Biol Med.
36. Yang BF, Lu YJ, Wang ZG (2009) MicroRNAs and apoptosis: implications in
the molecular therapy of human disease. Clin Exp Pharmacol Physiol 36:
951–960.
37. Cordes KR, Srivastava D (2009) MicroRNA regulation of cardiovascular
development. Circ Res 104: 724–732.
38. Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122:
6–7.
39. Nock NL, Wang X, Thompson CL, Song Y, Baechle D, et al. (2009) Defining
genetic determinants of the Metabolic Syndrome in the Framingham Heart
Study using association and structural equation modeling methods. BMC Proc 3
Suppl 7: S50.
40. Leung TH, Yam JW, Chan LK, Ching YP, Ng IO (2010) Deleted in liver cancer
2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K
signalling pathway. Liver Int 30: 1315–1323.
41. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, et al. (2010) MicroRNA-125b confers
the resistance of breast cancer cells to paclitaxel through suppression of pro-
apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285:
21496–21507.
42. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer.
N Engl J Med 363: 1938–1948.
43. Voss MJ, Moller MF, Powe DG, Niggemann B, Zanker KS, et al. (2011)
Luminal and basal-like breast cancer cells show increased migration induced by
hypoxia, mediated by an autocrine mechanism. BMC Cancer 11: 158.
44. Song J (2007) EMT or apoptosis: a decision for TGF-beta. Cell Res 17:
289–290.
45. Sequeira L, Dubyk CW, Riesenberger TA, Cooper CR, van Golen KL (2008)
Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell
diapedesis. Clin Exp Metastasis 25: 569–579.
46. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, et al. (2003) Deleted in
liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor
function and is underexpressed in hepatocellular carcinoma. J Biol Chem 278:
10824–10830.
47. Tang Y, Olufemi L, Wang MT, Nie D (2008) Role of Rho GTPases in breast
cancer. Front Biosci 13: 759–776.
48. Sahai E, Marshall CJ (2002) RHO-GTPases and cancer. Nat Rev Cancer 2:
133–142.
49. Paradiso A, Cardone RA, Bellizzi A, Bagorda A, Guerra L, et al. (2004) The
Na+-H+ exchanger-1 induces cytoskeletal changes involving reciprocal RhoA
and Rac1 signaling, resulting in motility and invasion in MDA-MB-435 cells.
Breast Cancer Res 6: R616–628.
50. Struckhoff AP, Rana MK, Worthylake RA (2011) RhoA can lead the way in
tumor cell invasion and metastasis. Front Biosci 16: 1915–1926.
miR-125b Induces Metastasis by Targeting STARD13
PLoS ONE | www.plosone.org 13 May 2012 | Volume 7 | Issue 5 | e35435